Twelve Points Wealth Management LLC Decreases Stock Position in Abrdn Life Sciences Investors (NYSE:HQL)

Twelve Points Wealth Management LLC lessened its position in Abrdn Life Sciences Investors (NYSE:HQLFree Report) by 10.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,425 shares of the company’s stock after selling 1,365 shares during the quarter. Twelve Points Wealth Management LLC’s holdings in Abrdn Life Sciences Investors were worth $154,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. NewEdge Advisors LLC increased its holdings in shares of Abrdn Life Sciences Investors by 3.1% in the first quarter. NewEdge Advisors LLC now owns 29,085 shares of the company’s stock valued at $401,000 after purchasing an additional 861 shares during the last quarter. Kingsview Wealth Management LLC increased its holdings in shares of Abrdn Life Sciences Investors by 2.8% in the third quarter. Kingsview Wealth Management LLC now owns 37,158 shares of the company’s stock valued at $508,000 after purchasing an additional 1,008 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in Abrdn Life Sciences Investors by 1.7% during the third quarter. Janney Montgomery Scott LLC now owns 72,249 shares of the company’s stock worth $901,000 after acquiring an additional 1,220 shares during the last quarter. Osaic Holdings Inc. increased its stake in Abrdn Life Sciences Investors by 1.7% during the second quarter. Osaic Holdings Inc. now owns 76,040 shares of the company’s stock worth $1,030,000 after acquiring an additional 1,271 shares during the last quarter. Finally, Royal Bank of Canada increased its stake in Abrdn Life Sciences Investors by 4.1% during the second quarter. Royal Bank of Canada now owns 32,894 shares of the company’s stock worth $446,000 after acquiring an additional 1,284 shares during the last quarter. Institutional investors and hedge funds own 19.70% of the company’s stock.

Abrdn Life Sciences Investors Price Performance

HQL stock opened at $13.55 on Friday. The business has a fifty day moving average of $13.83 and a two-hundred day moving average of $13.00. Abrdn Life Sciences Investors has a 52-week low of $11.34 and a 52-week high of $14.37.

Abrdn Life Sciences Investors Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Thursday, February 22nd will be paid a dividend of $0.39 per share. This is a boost from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.30. The ex-dividend date of this dividend is Wednesday, February 21st. This represents a $1.56 annualized dividend and a yield of 11.51%.

About Abrdn Life Sciences Investors

(Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.

Further Reading

Want to see what other hedge funds are holding HQL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abrdn Life Sciences Investors (NYSE:HQLFree Report).

Institutional Ownership by Quarter for Abrdn Life Sciences Investors (NYSE:HQL)

Receive News & Ratings for Abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.